Display options
Cite
Tantraworasin A, Saeteng S, Lertprasertsuke N, et al. Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer. Cancer Manag Res. 2013;5:77-84doi: 10.2147/CMAR.S45642.
Tantraworasin, A., Saeteng, S., Lertprasertsuke, N., Arreyakajohn, N., Kasemsarn, C., & Patumanond, J. (2013). Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer. Cancer management and research, 577-84. https://doi.org/10.2147/CMAR.S45642
Tantraworasin, Apichat, et al. "Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer." Cancer management and research vol. 5 (2013): 77-84. doi: https://doi.org/10.2147/CMAR.S45642
Tantraworasin A, Saeteng S, Lertprasertsuke N, Arreyakajohn N, Kasemsarn C, Patumanond J. Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer. Cancer Manag Res. 2013 Jun 06;5:77-84. doi: 10.2147/CMAR.S45642. Print 2013. PMID: 23785244; PMCID: PMC3682816.
Copy Download .nbib Format: NLM
Share it on

Cancer Manag Res. 2013 Jun 06;5:77-84. doi: 10.2147/CMAR.S45642. Print 2013.

Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer.

Cancer management and research

Apichat Tantraworasin, Somcharoen Saeteng, Nirush Lertprasertsuke, Nuttapon Arreyakajohn, Choosak Kasemsarn, Jayanton Patumanond

Affiliations

  1. General Thoracic Unit, Department of Surgery, Faculty of Medicine, Chiang Mai University Hospital, Chiang Mai, Thailand.

PMID: 23785244 PMCID: PMC3682816 DOI: 10.2147/CMAR.S45642

Abstract

BACKGROUND: Patients with completely resected non-small cell lung cancer (NSCLC) have an excellent outcome; however tumor recurs in 30%-77% of patients. This study retrospectively analyzed the clinicopathologic features of patients with any operable stage of NSCLC to identify the prognostic factors that influence tumor recurrence, including intratumoral blood vessel invasion (IVI), tumor size, tumor necrosis, and intratumoral lymphatic invasion.

METHODS: From January 2002 to December 2011, 227 consecutive patients were enrolled in this study. They were divided into two groups: the "no recurrence" group and the "recurrence" group. Recurrence-free survival was analyzed by multivariable Cox regression analysis, stratified by tumor staging, chemotherapy, and nodal involvement.

RESULTS: IVI, tumor necrosis, tumor diameter more than 5 cm, and nodal involvement were identified as independent prognostic factors of tumor recurrence. The hazard ratio (HR) of patients with IVI was 2.1 times higher than that of patients without IVI (95% confident interval [CI]: 1.4-3.2) (P = 0.001).The HR of patients with tumor necrosis was 2.1 times higher than that of patients without tumor necrosis (95% CI: 1.3-3.4) (P = 0.001). Patients who had a maximum tumor diameter greater than 5 cm had significantly higher risk of recurrence than patients who had a maximum tumor diameter of less than 5 cm (HR 1.9, 95% CI: 1.0-3.5) (P = 0.033).

CONCLUSION: IVI, tumor diameter more than 5 cm, and tumor necrosis are prognostic factors of tumor recurrence in completely resected NSCLC. Therefore, NSCLC patients, with or without nodal involvement, who have one or more prognostic factors of tumor recurrence may benefit from adjuvant chemotherapy for prevention of tumor recurrence.

Keywords: NSCLC; intratumoral blood vessel invasion; recurrence

References

  1. Ann Thorac Surg. 2006 Oct;82(4):1180-4 - PubMed
  2. Cancer. 1999 Nov 15;86(10):1976-84 - PubMed
  3. Cancer. 1988 May 15;61(10):2083-8 - PubMed
  4. Ann Thorac Surg. 2004 May;77(5):1769-73; discussion 1773 - PubMed
  5. J Thorac Cardiovasc Surg. 2006 May;131(5):988-93 - PubMed
  6. J Thorac Cardiovasc Surg. 2005 Jul;130(1):160-5 - PubMed
  7. Ann Thorac Surg. 2011 Apr;91(4):1059-65; discussion 1065 - PubMed
  8. J Clin Oncol. 2008 Jul 20;26(21):3543-51 - PubMed
  9. J Clin Oncol. 2008 May 20;26(15):2450-6 - PubMed
  10. N Engl J Med. 2005 Jun 23;352(25):2589-97 - PubMed
  11. World J Surg Oncol. 2009 Nov 12;7:87 - PubMed
  12. J Thorac Oncol. 2007 Aug;2(8):706-14 - PubMed
  13. Eur J Cardiothorac Surg. 2011 Sep;40(3):664-70 - PubMed
  14. Front Oncol. 2011 Nov 24;1:45 - PubMed
  15. J Thorac Oncol. 2011 Jan;6(1):48-54 - PubMed
  16. Cancer. 2007 Oct 1;110(7):1532-41 - PubMed
  17. J Thorac Oncol. 2009 Jun;4(6):671-3 - PubMed
  18. Ann Thorac Surg. 2001 Aug;72(2):352-6 - PubMed
  19. J Thorac Cardiovasc Surg. 1995 Sep;110(3):601-5 - PubMed
  20. Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 - PubMed
  21. Ann Thorac Surg. 2004 Nov;78(5):1748-53 - PubMed
  22. Cancer. 1995 Jun 15;75(12):2844-52 - PubMed
  23. Ann Thorac Surg. 2007 Jan;83(1):204-8 - PubMed
  24. J Thorac Oncol. 2011 Feb;6(2):244-85 - PubMed
  25. Eur J Cardiothorac Surg. 2008 May;33(5):799-804 - PubMed
  26. Ann Thorac Surg. 2004 Feb;77(2):421-5 - PubMed
  27. N Engl J Med. 2004 Jan 22;350(4):351-60 - PubMed
  28. Lung Cancer. 2010 Jun;68(3):398-402 - PubMed
  29. J Clin Oncol. 2008 Jul 20;26(21):3552-9 - PubMed
  30. J Thorac Cardiovasc Surg. 2008 Jan;135(1):44-9 - PubMed
  31. Ann Thorac Surg. 2010 Mar;89(3):864-9 - PubMed
  32. Chest. 2007 Jul;132(1):170-7 - PubMed
  33. Lung Cancer. 2009 Apr;64(1):71-8 - PubMed
  34. Lancet Oncol. 2006 Sep;7(9):719-27 - PubMed
  35. Cancer. 1995 Sep 1;76(5):787-96 - PubMed
  36. N Engl J Med. 2004 Apr 22;350(17):1713-21 - PubMed
  37. Chest. 2008 Mar;133(3):662-9 - PubMed
  38. J Thorac Cardiovasc Surg. 2009 Feb;137(2):429-34 - PubMed
  39. Eur J Cardiothorac Surg. 2004 Jul;26(1):173-82 - PubMed
  40. Ann Thorac Surg. 2006 Jul;82(1):220-6 - PubMed

Publication Types